Pfizer (PFE) Total Current Liabilities (2009 - 2026)
Pfizer (PFE) posted quarterly Total Current Liabilities of $34.3 billion for Q1 2026, down 5.77% year-over-year from $36.5 billion in Q1 2025, and down 7.13% quarter-over-quarter from $37.0 billion in Q4 2025.
Pfizer (PFE) Total Current Liabilities (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Total Current Liabilities for 18 consecutive years, with $34.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Current Liabilities fell 5.77% year-over-year to $34.3 billion; the TTM figure through Mar 2026 stood at $34.3 billion (down 5.77% YoY), while the FY2025 annual figure was $37.0 billion, down 13.98% from the prior year.
- Total Current Liabilities eased to $34.3 billion in Q1 2026 per PFE's latest filing, from $37.0 billion in the prior quarter.
- Across five years, Total Current Liabilities topped out at $47.8 billion in Q4 2023 and bottomed at $5.2 billion in Q3 2022.
- Historically, Total Current Liabilities has averaged $36.0 billion across 5 years, with a median of $37.7 billion in 2025.
- Annual changes were most pronounced in 2023 — Total Current Liabilities declined 26.92% — and 2024, when it surged 606.41%.
- Pfizer's Total Current Liabilities stood at $42.1 billion in 2022, then increased by 13.42% to $47.8 billion in 2023, then dropped by 10.04% to $43.0 billion in 2024, then fell by 13.98% to $37.0 billion in 2025, then retreated by 7.13% to $34.3 billion in 2026.
- Business Quant data shows PFE's Total Current Liabilities at $34.3 billion in Q1 2026, $37.0 billion in Q4 2025, and $36.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 32.65 Bn |
| Mar 29, 2026 | 34.35 Bn |
| Dec 31, 2025 | 36.98 Bn |
| Sep 28, 2025 | 36.60 Bn |
| Jun 29, 2025 | 37.73 Bn |
| Mar 30, 2025 | 36.45 Bn |
| Dec 31, 2024 | 43.00 Bn |
| Sep 29, 2024 | 43.21 Bn |
| Jun 30, 2024 | 43.82 Bn |
| Mar 31, 2024 | 40.50 Bn |
| Dec 31, 2023 | 47.79 Bn |
| Sep 30, 2023 | 6.12 Bn |
| Jul 2, 2023 | 34.65 Bn |
| Apr 2, 2023 | 36.56 Bn |
| Dec 31, 2022 | 42.14 Bn |
| Sep 30, 2022 | 5.24 Bn |
| Jul 3, 2022 | 47.41 Bn |
| Apr 3, 2022 | 39.27 Bn |
| Dec 31, 2021 | 42.67 Bn |
| Oct 3, 2021 | 5.13 Bn |